Notice of Full Year Results

Destiny Pharma PLC

08 April 2024

 

08 April 2024

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Notice of Full Year Results and Investor Presentation

Brighton, United Kingdom - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, will announce its financial results for the year ended 31 December 2023, on Thursday 25 April 2024.

Chris Tovey, Chief Executive Officer, and Shaun Claydon, Chief Financial Officer, will host a briefing for analysts at 8.30am BST followed by a presentation to all existing and potential shareholders at 11:00am BST held via the Investor Meet Company platform. Further details for the analyst briefing will be shared by invitation in due course.

Questions can be submitted pre-event via the Investor Meet Company dashboard up until 09:00am BST the day before the meeting, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free, and add to meet Destiny Pharma

plc via: https://www.investormeetcompany.com/destiny-pharma-plc/register-investor

Investors who already follow Destiny Pharma plc on the Investor Meet Company platform will automatically be invited.

For further information, please contact:

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

[phone]

[e-mail]

FTI Consulting

Ben Atwell / Simon Conway / Michael Trace

[phone]

[e-mail]

Shore Capital (Nominated Advisor and Broker)

Daniel Bush / James Thomas / Lucy Bowden

[phone]

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.

For further information on the company, please visit www.destinypharma.com

 

END